clinical trial · NCT04998201
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Mixed DyslipidemiaARO-APOC3Placebo
brief summary
Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.
started
Sep 28, 2021
primary completion
Feb 10, 2023
completion
Aug 14, 2023
last updated
Apr 14, 2026
official title
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol